TScan Therapeutics is developing cellular therapies across multiple solid tumors in which autologous participant-derived T cells are engineered to express a T cell receptor that recognizes cancer-associated antigens presented on specific Human Leukocyte Antigen (HLA) molecules. The purpose of this screening study is to collect samples to conduct HLA genotyping, HLA Loss of Heterozygosity (LOH) and expression of Tumor-associated Antigens (TAA) testing. These results will be used to determine if participants meet the eligibility criteria for these parameters and could potentially be enrolled in a TScan clinical treatment study.
Screening Study to Determine HLA Type, HLA Loss of Heterozygosity Status and Tumor Antigen Expression in Participants With Locally Advanced (Unresectable) or Metastatic Solid Tumors
This multicenter screening study will be conducted to determine a participant's tumor antigen expression profile, HLA genotype and loss of HLA for TScan sponsored clinical treatment study(s). No treatment intervention will occur as part of this screening study.
Participants will be required to provide a buccal swab to assess their HLA status. If they are positive for certain types of HLA, participants will provide saliva sample to assess HLA loss of heterozygosity. In parallel, archival tissue (less than 8 months old) will be needed to assess for tumor antigen expression. If archival tissue is older than 8 months, a fresh tumor biopsy will be required at the time of the subsequent visit.
If eligible, participants will be referred to appropriate available interventional trial(s) at the discretion of the Investigator.